US11045432B2 - Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof - Google Patents

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof Download PDF

Info

Publication number
US11045432B2
US11045432B2 US15/247,524 US201615247524A US11045432B2 US 11045432 B2 US11045432 B2 US 11045432B2 US 201615247524 A US201615247524 A US 201615247524A US 11045432 B2 US11045432 B2 US 11045432B2
Authority
US
United States
Prior art keywords
epinephrine
composition
free
pharmaceutical composition
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/247,524
Other versions
US20170049721A1 (en
Inventor
John Scott Karolchyk
Mark L. Baum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow IP LLC
Original Assignee
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/247,524 priority Critical patent/US11045432B2/en
Application filed by Harrow IP LLC filed Critical Harrow IP LLC
Assigned to IMPRIMIS PHARMACEUTICALS, INC. reassignment IMPRIMIS PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAUM, MARK L., KAROLCHYK, JOHN SCOTT
Publication of US20170049721A1 publication Critical patent/US20170049721A1/en
Assigned to SWK FUNDING LLC, AS COLLATERAL AGENT reassignment SWK FUNDING LLC, AS COLLATERAL AGENT INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: IMPRIMIS PHARMACEUTICALS, INC.
Assigned to HARROW IP, LLC reassignment HARROW IP, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IMPRIMIS PHARMACEUTICALS, INC.
Assigned to SWK FUNDING LLC, AS COLLATERAL AGENT reassignment SWK FUNDING LLC, AS COLLATERAL AGENT AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Assignors: HARROW IP, LLC
Assigned to HARROW IP, LLC reassignment HARROW IP, LLC RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: SWK FUNDING LLC
Priority to US17/330,023 priority patent/US20210275471A1/en
Application granted granted Critical
Publication of US11045432B2 publication Critical patent/US11045432B2/en
Priority to US17/384,373 priority patent/US20210346318A1/en
Assigned to B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT reassignment B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HARROW EYE, LLC, HARROW HEALTH, INC., HARROW IP, LLC, IMPRIMIS NJOF, LLC, IMPRIMISRX NJ, LLC, IMPRIMISRX, LLC, VISIONOLOGY EQUITY, LLC, VISIONOLOGY MSO, INC., VISIONOLOGY, INC.
Assigned to OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT reassignment OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT PATENT SECURITY AGREEMENT Assignors: HARROW IP, LLC
Assigned to IMPRIMISRX NJ, LLC, VISIONOLOGY EQUITY, LLC, HARROW HEALTH, INC., HARROW IP, LLC, HARROW EYE, LLC, IMPRIMISRX, LLC, VISIONOLOGY, INC., IMPRIMIS NJOF, LLC, VISIONOLOGY MSO, INC. reassignment IMPRIMISRX NJ, LLC TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556 Assignors: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
    • B65D25/02—Internal fittings
    • B65D25/04—Partitions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates generally to the field of ophthalmology and more specifically to injectable ophthalmological compositions comprising epinephrine, and to methods of preparing such compositions.
  • Epinephrine (EPI or epi) is a drug that is frequently used in ophthalmological treatments, procedures and surgeries, e.g., cataract surgery or glaucoma surgery. Epinephrine is known to be used for such purposes either alone or as an active ingredient in a composition, e.g., in intracameral epi-Shugarcaine for intraoperative floppy iris syndrome (IFIS) and pupil dilation. Epinephrine is a perishable product with limited shelf life and limited stability. Epinephrine quite easily gets oxidized to form adrenochrome (chemically, catecholamine quinone). The oxidation causes deactivation of epinephrine and the concomitant loss of its valuable medicinal properties. Therefore, most commercially available epinephrine contains preservatives and stabilizers, typically bisulfites, for a prolonged shelf life and stability.
  • epinephrine with preservatives is undesirable as it can cause toxicity in the eye, putting patients at risk for toxic anterior segment syndrome (TASS), an acute inflammation of the anterior segment.
  • TASS toxic anterior segment syndrome
  • most TASS cases are cured with topical steroids, severe cases can lead to cornea transplantation and iris atrophy. Having alternative non-toxic epinephrine-based compositions and procedures utilizing them that are safer but equally effective is, therefore, desirable.
  • This disclosure provides an alternative procedure that includes an intraocular injection that employs preservative- and sulfite-free compositions of epinephrine or essentially preservative- and sulfite-free compositions of the same.
  • Such alternative procedure can achieve patient outcomes that are as good as, or better than, the current regimen, removing the issues of toxicity.
  • This patent application discloses epinephrine-based pharmaceutical compositions suitable for intraocular injections that can achieve such positive patient outcomes, and methods of fabricating and administering the same.
  • FIG. 1 shows schematically one kind of a bicameral container in which a method of for preparing a pharmaceutical composition can be carried out according to one embodiment of the invention.
  • composition(s) for intraocular injection is (are) provided, the composition(s) comprising a therapeutically effective quantity of lyophilized epinephrine and/or phenylephrine, the pharmaceutical composition(s) being free of sulfites and is free of preservatives, or being essentially free of sulfites and being essentially free of preservatives, or being free of sulfites and being essentially free of preservatives, or being essentially free of sulfites and being free of preservatives.
  • composition(s) for intraocular injection comprising a therapeutically effective quantity of lyophilized epinephrine and/or phenylephrine, and at least one metal chelator such as, e.g., ethylenediaminetetraacetic acid or acetylcysteine and pharmaceutically acceptable salts thereof.
  • metal chelator such as, e.g., ethylenediaminetetraacetic acid or acetylcysteine and pharmaceutically acceptable salts thereof.
  • a method for preparing a pharmaceutical composition for intraocular injection comprising lyophilizing the aqueous composition comprising a therapeutically effective quantity of epinephrine and/or phenylephrine that is free or essentially free of sulfites and is free or essentially free of preservatives and reconstituting the composition immediately prior to the use thereof, to obtain thereby the pharmaceutical composition for intraocular injection.
  • lyophilized epinephrine and/or phenylephrine-containing composition(s) described herein may further optionally include therapeutically effective quantity (or quantities) of one or several other compounds such as anesthetic(s) (e.g., lidocaine) and/or non-steroid anti-inflammatory drugs (NSAID) such as ketorolac.
  • anesthetic e.g., lidocaine
  • NSAID non-steroid anti-inflammatory drugs
  • “About” as used herein means that a number referred to as “about” comprises the recited number plus or minus 1-10% of that recited number. For example, “about” 100 degrees can mean 95-105 degrees or as few as 99-101 degrees depending on the context. Whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; i.e., meaning only 1, only 2, only 3, etc., up to and including only 20.
  • composition is defined as a chemical or biological compound or substance, or a mixture or combination of two or more such compounds or substances, intended for use in the medical diagnosis, cure, treatment, or prevention of disease or pathology.
  • intraocular injection refers to an injection that is administered by entering the eyeball of the patient.
  • preservative refers to a chemical substance that is added to a pharmaceutical composition to prevent the pharmaceutical composition from deterioration, decomposition or degradation or to substantially reduce or decelerate the degree and/or the speed of such deterioration, decomposition or degradation.
  • preservative-free means a pharmaceutical composition that does not include a preservative or includes not more than a trace amount of a preservative.
  • the pharmaceutical composition can be substantially free of preservative or alternatively include not more than a trace amount of a preservative.
  • metal chelators such as EDTA defined below are not considered preservatives. Accordingly, compositions that comprise metal chelators such as EDTA are considered preservative-free if they include no other preservative(s).
  • Trace amounts of preservatives can include relatively low concentrations or amounts of preservatives in a pharmaceutical composition.
  • relatively low concentrations of preservatives include concentrations of about 1 ⁇ M or less, or about 1% of the pharmaceutical composition by weight or less or about 1 ⁇ g per dosage unit of pharmaceutical composition or less.
  • relatively low concentrations of preservatives include concentrations of about 100 nM or less, about 10 nM or less, about 1 nM or less, about 100 pM or less, about 10 pM or less or about 1 pM or less; or about 0.1% or less, or about 0.01% or less, or about 0.001% or less or about 0.0001% or less, each of the pharmaceutical composition by weight.
  • relatively low amounts of preservatives in pharmaceutical compositions include pharmaceutical compositions wherein preservatives are provided at about 100 ng or less, about 10 ng or less, about 1 ng or less, about 100 pg or less, about 10 pg or less or about 1 pg or less, each per dosage unit of pharmaceutical composition.
  • anti-oxidant refers to a chemical substance that is added to a pharmaceutical composition to prevent or inhibits the oxidation of molecules that are present in the active component of the composition, such as epinephrine. It is explicitly understood that for the purposes of the present application, anti-oxidants are not considered preservatives. Accordingly, compositions that optionally comprise anti-oxidants as described below are considered preservative-free if they include no other preservative(s).
  • sulfite refers to compounds that comprise the sulfite ion SO 3 2- such as normal salts of sulfurous acid H 2 SO 3 .
  • sulfite is also inclusive of bisulfites, i.e., compounds that comprise the bisulfate ion HSO 3 ⁇ such as acid salts of sulfurous acid.
  • sulfite-free means a pharmaceutical composition that does not include a sulfite or includes a relatively low concentration or amount of a sulfite.
  • the pharmaceutical composition can be substantially free of sulfite or have not more than a trace amount of sulfite.
  • metal chelators such as EDTA defined below are not considered sulfites. Accordingly, compositions that comprise metal chelators such as EDTA are considered sulfite-free if they include no other sulfite(s).
  • Trace amounts of sulfites can include relatively low concentrations or amounts of sulfites in a pharmaceutical composition. Relatively low concentrations of sulfites include concentrations include concentrations of about 1 ⁇ M or less, or about 1% of the pharmaceutical composition by weight or less or about 1 ⁇ g per dosage unit of pharmaceutical composition or less.
  • relatively low concentrations of sulfites include concentrations of about 100 nM or less, about 10 nM or less, about 1 nM or less, about 100 pM or less, about 10 pM or less or about 1 pM or less; or about 0.1% or less, or about 0.01% or less, or about 0.001% or less or about 0.0001% or less, each of the pharmaceutical composition by weight.
  • relatively low amounts of sulfites in pharmaceutical compositions include pharmaceutical compositions wherein preservatives are provided at about 100 ng or less, about 10 ng or less, about 1 ng or less, about 100 pg or less, about 10 pg or less or about 1 pg or less, each per dosage unit of pharmaceutical composition.
  • freeze-drying a dehydration process that includes freezing the material and then reducing the pressure to allow the frozen water in the material to sublimate
  • partially lyophilized refers to compositions that comprise both a lyophilized portion of a product and a non-lyophilized portion of the same.
  • epinephrine which is synonymous with “adrenaline” (the two terms may be used interchangeably) refers to any stereoisomer of 4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol, a chemical compound having the following chemical structure (the R-stereoisomer is shown):
  • phenylephrine refers to any stereoisomer of 3-[1-hydroxy-(methylamino)ethyl]phenol, a chemical compound having the following chemical structure (also the R-stereoisomer is shown):
  • EPI-Shugarcaine refers to a composition consisting of about 25% (vol.) of 1:1,000 bisulfite-free aqueous solution of epinephrine, about 19% (vol.) of preservative-free lidocaine and the balance, BSS Plus® (balanced salt solution available from Alcon Laboratories of Fort Worth, Tex.).
  • neural refers to a substance that that causes loss of sensation and therefore induces insensitivity or low sensitivity to pain.
  • lidocaine refers to 2-diethylamino-N-(2,6-dimethylphenyl)acetamide, a chemical compound having the following chemical structure:
  • EDTA is 2-( ⁇ 2[bis(carboxymethyl)amino]ethyl ⁇ (carboxymethyl)amino) acetic acid (a chemical compound that is also known under several other names such as edetic acid or ethylenediaminetetraacetic), and its various protonated forms, EDTA having the following chemical structure:
  • chelating agent or “metal chelator” refer to a chemical compound that coordinates with a metal to form a chelate, which is a compound containing an organic ligand bonded to a central metal atom at two or more points.
  • non-steroid anti-inflammatory drugs or “NSAID” refer to a class of compounds that are free of any steroid moieties yet are capable of providing analgesic, antipyretic and/or anti-inflammatory effects.
  • ketorolac refers to a chemical composition comprising, in the 1:1 mass ratio, 2-amino-2-(hydroxymethyl)-1,3-propanediol, a chemical compound having the chemical structure NH 2 —C—(CH 2 OH) 3 and 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, a chemical compound having the following chemical structure:
  • salt refers to an ionic compound which is a product of the neutralization reaction of an acid and a base.
  • phacoemulsification refers to an ophthalmological surgical procedure in which the eye's internal lens is ultrasonically emulsified and aspirated from the eye.
  • carrier refers to a substance that serves as a vehicle for improving the efficiency of delivery and the effectiveness of a pharmaceutical composition.
  • a carrier for the purposes of the instant application is water such as de-ionized sterile water.
  • terapéuticaally effective amount is defined as the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, medical doctor or other clinician.
  • pharmaceutically acceptable is defined as a carrier, whether diluent or excipient, that is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • administration of a composition or “administering a composition” is defined to include an act of providing a compound or pharmaceutical composition of the application to the subject in need of treatment.
  • Intracameral epinephrine is commonly used off-label to dilate and stabilize the pupil intraoperatively by preventing intraoperative floppy iris syndrome.
  • commonly available epinephrine is frequently quite toxic.
  • Those having ordinary skill in the art believe that the toxicity is caused by the high buffer capacity of the bisulfate that is present in the epinephrine solution rather than by the epinephrine itself. It is, therefore, desirable to only use for direct intracameral injection preservative-free preparations of epinephrine that are also bisulfite-free.
  • compositions for intraocular injections that are free of the above-mentioned problems, drawbacks and defects.
  • the compositions are preservative-free and sulfite-free and include an active component comprising, consisting essentially of, or consisting of a therapeutically effective quantity of epinephrine or adrenaline or pharmaceutically acceptable salts thereof (e.g., a hydrochloride) and a pharmaceutically acceptable carrier therefor.
  • an active component comprising, consisting essentially of, or consisting of a therapeutically effective quantity of epinephrine or adrenaline or pharmaceutically acceptable salts thereof (e.g., a hydrochloride) and a pharmaceutically acceptable carrier therefor.
  • Bisulfite-free epinephrine is available from American Regent Laboratories of Shirley, N.Y.
  • the active component may optionally include other compounds, non-limiting examples of which include phenylephrine, EPI-Shugarcaine and/or tropicamide.
  • Some anti-oxidants may be also optionally used, if desired, as a part of the active component, i.e., in combination with epinephrine, to provide some additional stability to epinephrine.
  • Non-limiting examples of acceptable anti-oxidants that may be so used include ascorbic acid, vitamin E, glutathione and acetylcysteine. It has to be kept in mind that these additional anti-oxidants typically provide only limited stability to epinephrine, usually up to 60 days, when the composition is kept refrigerated.
  • the active component may optionally include still other compounds, such as one or several anesthetics (e.g., lidocaine) and/or one or several non-steroid anti-inflammatory drug(s).
  • anesthetics e.g., lidocaine
  • non-steroid anti-inflammatory drug(s) include proparacaine, procaine, tetracaine and combinations thereof.
  • acceptable NSAID's that can be so utilized include ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.
  • embodiments of the invention envision preservative-free and sulfite-free compositions having an active component, which includes any combination of epinephrine, and/or phenylephrine and/or EPI-Shugarcaine, and in addition, optionally, any combination of anesthetic(s) and/or non-steroid anti-inflammatory drug(s).
  • active component which includes any combination of epinephrine, and/or phenylephrine and/or EPI-Shugarcaine, and in addition, optionally, any combination of anesthetic(s) and/or non-steroid anti-inflammatory drug(s).
  • at least one of epinephrine, phenylephrine EPI-Shugarcaine and tropicamide is to be present in the active component, while the presence of any other additional components mentioned above is optional.
  • the contents of the active component in the pharmaceutical compositions of the present application may be between about 0.001 and about 0.5 mass %, such as between about 0.01 and about 0.3 mass %, for example, between about 0.03 and about 0.1 mass %.
  • the compositions described in the present application further include certain additives, but, as indicated above, are free of preservatives and are free of sulfites.
  • NSAID(s) are to be used, one having ordinary skill in the art may select a proper ratio between epinephrine, and/or phenylephrine and/or EPI-Shugarcaine and NSAID(s).
  • the mass ratio between phenylephrine and ketorolac may be between about 10:1 and about 3:1, such as about 4:1.
  • a pharmaceutical composition for intraocular injection further comprises a quantity of least one chelating agent such as a metal chelator.
  • a metal chelator such as a metal chelator.
  • an acceptable chelating agent that may be used in combination with epinephrine is ethylenediaminetetraacetic acid (EDTA) or pharmaceutically acceptable salts thereof, which is both a chelator and a stabilizer.
  • EDTA ethylenediaminetetraacetic acid
  • One salt of EDTA that can provide stabilization of epinephrine is EDTA disodium.
  • Other salts of EDTA non-limiting examples of which include EDTA calcium disodium and EDTA magnesium disodium, may be also used instead of, or in combination with, EDTA disodium.
  • the contents of the chelating agent in the pharmaceutical compositions of the present application may be (expressed as the chelating agent to epinephrine mass ratio) between about 4:1 and 1:4, for example, about 1:2 (i.e., about 0.5 mg of EDTA per 1 mg of epinephrine).
  • Those having ordinary skill in the art may select a specific chelating agent based on the needs of a particular patient or on the desired properties of the final composition and may also adjust the concentration of the active component and/or of the chelating agent in the composition, if desired.
  • the composition may optionally include other components such as additives, adjuvants, diluents, modifiers, excipients, etc., so long as the composition remains both preservative-free and sulfite-free within the meaning of “preservative” defined above.
  • acetylcysteine acetylcysteine which is capable of eliminating, or at least reducing the quantity of, free radicals, and of providing nourishment to the eye
  • glutathione glutathione
  • ascorbic acid vitamin E and balanced salts solution.
  • composition I can be prepared first.
  • composition I a quantity of an active ingredient such as epinephrine, a quantity of a metal chelator such as EDTA, optionally, a quantity of at least one anesthetic, optionally, a quantity of at least one non-steroid anti-inflammatory drug and, optionally, a quantity of an non-preservative additive such as sodium chloride NaCl (e.g., if isotonicity has to be adjusted), may be combined in a depyrogenated glass container. The mixture may be then dissolved in sterile de-ionized water to form a clear aqueous solution.
  • an active ingredient such as epinephrine
  • a quantity of a metal chelator such as EDTA optionally, a quantity of at least one anesthetic, optionally, a quantity of at least one non-steroid anti-inflammatory drug and, optionally, a quantity of an non-preservative additive such as sodium chloride NaCl (e.g., if isotonicity has to
  • composition I Each of the ingredients used to make composition I is to be used in pre-determined quantity so that the final pharmaceutical composition have a desired ratio between the ingredients and a desired concentration of each of them. Those having ordinary skill in the art can determine the desired ratios and concentrations.
  • the pH of the solution may be adjusted to a pH level ranging from slightly acidic, e.g., about 6.0, to slightly basic, e.g., about 8.0.
  • the process of lyophilization of composition I may then be conducted to obtain the lyophilized product, composition II.
  • the solution may be optionally de-gassed followed by freezing at low temperatures (e.g., ⁇ 70° C. or lower) for a period of time (e.g., at least 24 hours) to allow the solution to completely solidify and to form proper ice crystals.
  • the frozen composition is subjected to a vacuum of at least 30 mm Hg for a period of time (e.g., at least 24 hours).
  • a vacuum of at least 30 mm Hg for a period of time (e.g., at least 24 hours).
  • the water sublimates from the frozen solution (i.e., transitions from the solid to the gas phase bypassing the liquid phase) to form a completely dry, powder-like substance which is the lyophilized composition II.
  • composition II is a completely lyophilized preservative-free and sulfite-free pharmaceutical composition containing the active ingredient (e.g., epinephrine), the metal chelator (e.g., EDTA) and, optionally, other ingredients discussed above, if such optional ingredients are used in preparing composition I. Not more than trace quantity of residual water would be typically contained in composition II after the process of lyophilization is complete.
  • active ingredient e.g., epinephrine
  • the metal chelator e.g., EDTA
  • Not more than trace quantity of residual water would be typically contained in composition II after the process of lyophilization is complete.
  • Composition II i.e., the lyophilized dry epinephrine-based composition that is preservative-free and sulfite-free prepared according to methods described herein has remained stable for several months and is expected to continue being stable for as long as two years. Stability can be evaluated by those having ordinary skill in the art according to one or more of various methods, e.g., by the retention of potency after storage for a period of time, by showing that no loss (or not more than negligible loss) of concentration of epinephrine has occurred during the period of storage, or by visual observations such as no change in color.
  • the dry composition II is to be reconstituted immediately prior to its use, for example, 1 hr or less before the surgery, or 30 minutes or less.
  • a quantity of sterile de-ionized water for injection is to be added to the dry composition and a clear solution can thus obtained.
  • the concentration of the active component such as epinephrine that is desirable to have for the injection determines the quantity of water to be added to the dry composition, to be chosen by one having ordinary skill in the art.
  • the final product to be injected contains about 1 mg/mL of epinephrine, i.e., is a 1:1,000 solution.
  • composition II As is clear from the discussion above, the use of lyophilized and then reconstituted composition II is then typically envisioned according to embodiments of the instant application. However, in other embodiments that can be also practiced, composition I described above may be optionally used for re-constitution, with or without pure sterile de-ionized water for injection being added also.
  • the pharmaceutical composition comprises a fully lyophilized portion (i.e., composition II), a non-lyophilized portion (i.e., composition I) and, optionally, an extra quantity of pure sterile de-ionized water.
  • Those having ordinary skill in the art can determine the quantities of the fully lyophilized and non-lyophilized portions and of water so as to achieve the desired ratios of the ingredients and their concentrations.
  • a variety of apparatuses can be used for reconstituting the composition.
  • water can be added to the dry composition in a single container such as a vial. Once a clear solution has been formed, it can be collected by a syringe and injected or it can be picked up by an eye dropper or a pipette and administered as drops, if desired.
  • Those skilled in the art will use an appropriate apparatus if the composition is to be administered as a spray.
  • the dry composition can be mixed with sterile water or with a balanced salt solution in an infusion bottle, to be delivered in the phacoemulsification procedure if desired.
  • a bicameral container can be used.
  • a bicameral container there may be two sections separated by a partition or a seal.
  • One section will contain the dry composition described above and the second section will contain sterilized water.
  • the partition or the seal
  • the partition will prevent the contents of the two sections from combining.
  • the partition or the seal
  • a bicameral container 100 illustrated schematically by FIG. 1 may be used.
  • the bicameral container 100 having essentially a cylindrical shape comprises first section 1 into which a quantity of lyophilized composition 2 is placed.
  • Container 100 further comprises second section 3 into which a quantity of a carrier (i.e., in this embodiment sterilized water) 4 is placed.
  • the two sections are separated by partition 5 which prevents lyophilized composition 2 from uncontrollably mixing with water 4 .
  • partition 5 may include a one-way valve (not shown). Any typical standard one-way valve known to those having ordinary skill in the art may be utilized for this purpose.
  • the lyophilized composition 2 and water 4 may change places, i.e., the lyophilized composition 2 may be placed into the second section 3 and water 4 into the first section 1 .
  • the container 100 still includes partition 5 .
  • a pressure may be applied to carrier 4 using moveable plunger 6 .
  • the valve opens thus eliminating the partition between sections 1 and 3 and allowing carrier 4 to flow from section 3 into section 1 to mix with the lyophilized composition 2 .
  • a reconstituted pharmaceutical composition is obtained, to be administered to a patient.
  • the plunger 6 can comprise a protrusion or puncture component on the partition facing surface of the plunger 6 which when directional force is applied to the plunger the protrusion or puncture component pierces the partition 5 and allows the carrier 4 to flow from the second section 3 into the first section 1 .
  • a needle or a cannula (not shown) may be attached to device 100 at point 7 , and the composition may be then injected by using the device 100 (with the needle attached to it) as a syringe.
  • the process of lyophilization described above may be carried out directly in the device 100 .
  • a liquid composition 6 may be placed into section 1 of the device 100 prior to being lyophilized, followed by lyophilization by vacuum freeze-drying as discussed above, i.e, thereby producing lyophilized composition 2 .
  • section 1 of the device 100 will have lyophilized composition 2 contained within section 1 followed by the process of reconstituting lyophilized composition 2 as described above.
  • the reconstituted composition can then be used for surgically treating an ophthalmological disease, condition, disorder, syndrome or pathology in a mammalian subject such a human when it is necessary to administer an active component described in the application, e.g., epinephrine, as a part of surgical treatment.
  • an active component described in the application e.g., epinephrine
  • the reconstituted composition can be also used for treating of variety of animals, such as cats, dogs and farm animals if necessary.
  • Non-limiting examples of the ophthalmological disease, condition, disorder, syndrome or pathology to be treated include cataract surgery, glaucoma surgery, surgery to treat diseases of retina and prevention of floppy iris syndrome that may otherwise occur during other kinds of eye surgery.
  • the above described compositions are primarily to be delivered to an eye of the patient by an intraocular injection, some alternative methods of delivery may be also acceptable if desired. Examples of such alternative methods include delivery via eye drops or via a spray as mentioned above.
  • Those skilled in the art will formulate most appropriate eye drop and/or spray formulation(s) using lyophilized compositions described above, according to the best pharmaceutical practices.
  • kits are provided.
  • the kit includes a sealed container approved for the storage of pharmaceutical compositions, the container containing one of the above-described pharmaceutical compositions.
  • An instruction for the use of the composition and the information about the composition are to be included in the kit.
  • a pharmaceutical composition was prepared as described below. The following products were used in the amounts and concentrations specified, sufficient to prepare 100 vials of 1:1,000 lyophilized injections (1 mg/mL): 1.2 mg per vial.
  • the solution obtained as described above was filtered through 0.22 micron Supor filters into depyrogenated, sterilized (by autoclaving) vials, partially capped with three prong lyophilization stoppers and immediately frozen at about ⁇ 71° C. for about 24 hours to allow complete freezing and proper ice crystal formation. Degassing of solution prior to freeze-drying is optional but not necessary in this method.
  • the final product was tested chromatographically (HPLC) for potency and stability after being stored for some time. After about 5 weeks and again after about 4 months it remained stable and has retained its potency. No visually perceptible change of color has been observed.
  • Example 1 The composition prepared as described in Example 1 was then re-constituted about 30 minutes prior to being administered to a patient. A quantity of sterile water for injection was added to the dry composition prepared as described in Example 1 in a vial and a clear solution was obtained. The final product ready for injection contained about 1 mg/mL of epinephrine, i.e., was a 1:1,000 aqueous solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Description

This application is a continuation-part-application of U.S. patent application Ser. No. 14/506,120 filed on Oct. 3, 2014 entitled “Epinephrine-Based Compositions and Methods for Fabricating Thereof,” the entire contents of which is hereby incorporated by reference, and to which it claims priority under 35 U.S.C. § 120, and which claims priority under 35 U.S.C. § 119(e) to each of the following U.S. Provisional Applications No. 61/886,269 filed on Oct. 3, 2013 entitled “Epinephrine Compositions for Intraocular Administration and Methods for Fabricating Thereof,” No. 61/892,872 filed on Oct. 18, 2013 entitled “Epinephrine-Based Compositions and Methods for Fabricating Thereof” and No. 61/947,778 filed on Mar. 4, 2014 entitled “Epinephrine Compositions for Intraocular Administration and Methods for Fabricating Thereof” the entire contents of each of which is hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates generally to the field of ophthalmology and more specifically to injectable ophthalmological compositions comprising epinephrine, and to methods of preparing such compositions.
BACKGROUND
Epinephrine (EPI or epi) is a drug that is frequently used in ophthalmological treatments, procedures and surgeries, e.g., cataract surgery or glaucoma surgery. Epinephrine is known to be used for such purposes either alone or as an active ingredient in a composition, e.g., in intracameral epi-Shugarcaine for intraoperative floppy iris syndrome (IFIS) and pupil dilation. Epinephrine is a perishable product with limited shelf life and limited stability. Epinephrine quite easily gets oxidized to form adrenochrome (chemically, catecholamine quinone). The oxidation causes deactivation of epinephrine and the concomitant loss of its valuable medicinal properties. Therefore, most commercially available epinephrine contains preservatives and stabilizers, typically bisulfites, for a prolonged shelf life and stability.
However, using epinephrine with preservatives is undesirable as it can cause toxicity in the eye, putting patients at risk for toxic anterior segment syndrome (TASS), an acute inflammation of the anterior segment. Although most TASS cases are cured with topical steroids, severe cases can lead to cornea transplantation and iris atrophy. Having alternative non-toxic epinephrine-based compositions and procedures utilizing them that are safer but equally effective is, therefore, desirable.
This disclosure provides an alternative procedure that includes an intraocular injection that employs preservative- and sulfite-free compositions of epinephrine or essentially preservative- and sulfite-free compositions of the same. Such alternative procedure can achieve patient outcomes that are as good as, or better than, the current regimen, removing the issues of toxicity. This patent application discloses epinephrine-based pharmaceutical compositions suitable for intraocular injections that can achieve such positive patient outcomes, and methods of fabricating and administering the same.
BRIEF DESCRIPTION OF FIGURES
FIG. 1 shows schematically one kind of a bicameral container in which a method of for preparing a pharmaceutical composition can be carried out according to one embodiment of the invention.
 SUMMARY
According to one embodiment of the invention, pharmaceutical composition(s) for intraocular injection is (are) provided, the composition(s) comprising a therapeutically effective quantity of lyophilized epinephrine and/or phenylephrine, the pharmaceutical composition(s) being free of sulfites and is free of preservatives, or being essentially free of sulfites and being essentially free of preservatives, or being free of sulfites and being essentially free of preservatives, or being essentially free of sulfites and being free of preservatives.
According to another embodiment of the invention, pharmaceutical composition(s) for intraocular injection is (are) provided, the composition(s) comprising a therapeutically effective quantity of lyophilized epinephrine and/or phenylephrine, and at least one metal chelator such as, e.g., ethylenediaminetetraacetic acid or acetylcysteine and pharmaceutically acceptable salts thereof.
According to yet another embodiment of the invention, a method for preparing a pharmaceutical composition for intraocular injection is provided, the method comprising lyophilizing the aqueous composition comprising a therapeutically effective quantity of epinephrine and/or phenylephrine that is free or essentially free of sulfites and is free or essentially free of preservatives and reconstituting the composition immediately prior to the use thereof, to obtain thereby the pharmaceutical composition for intraocular injection.
According to yet another embodiment of the invention, lyophilized epinephrine and/or phenylephrine-containing composition(s) described herein may further optionally include therapeutically effective quantity (or quantities) of one or several other compounds such as anesthetic(s) (e.g., lidocaine) and/or non-steroid anti-inflammatory drugs (NSAID) such as ketorolac.
DETAILED DESCRIPTION A. Terms, Definitions and Abbreviations
Unless specific definitions are provided, the nomenclatures utilized in connection with, and the laboratory procedures and techniques of analytical chemistry, synthetic organic and inorganic chemistry described herein, are those known in the art. Standard chemical symbols are used interchangeably with the full names represented by such symbols. Thus, for example, the terms “hydrogen” and “H” are understood to have identical meaning. Standard techniques may be used for chemical syntheses, chemical analyses, formulating compositions and testing them. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention claimed. As used herein, the use of the singular includes the plural unless specifically stated otherwise. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
As used herein, “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “includes,” and “included,” is not limiting.
“About” as used herein means that a number referred to as “about” comprises the recited number plus or minus 1-10% of that recited number. For example, “about” 100 degrees can mean 95-105 degrees or as few as 99-101 degrees depending on the context. Whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; i.e., meaning only 1, only 2, only 3, etc., up to and including only 20.
The term “pharmaceutical composition” is defined as a chemical or biological compound or substance, or a mixture or combination of two or more such compounds or substances, intended for use in the medical diagnosis, cure, treatment, or prevention of disease or pathology.
The term “intraocular injection” refers to an injection that is administered by entering the eyeball of the patient.
The term “preservative” for the purposes of the present invention refers to a chemical substance that is added to a pharmaceutical composition to prevent the pharmaceutical composition from deterioration, decomposition or degradation or to substantially reduce or decelerate the degree and/or the speed of such deterioration, decomposition or degradation.
Accordingly “preservative-free” means a pharmaceutical composition that does not include a preservative or includes not more than a trace amount of a preservative. Thus, the pharmaceutical composition can be substantially free of preservative or alternatively include not more than a trace amount of a preservative. It is explicitly understood that for the purposes of the present application, metal chelators such as EDTA defined below are not considered preservatives. Accordingly, compositions that comprise metal chelators such as EDTA are considered preservative-free if they include no other preservative(s).
Trace amounts of preservatives can include relatively low concentrations or amounts of preservatives in a pharmaceutical composition. In certain embodiments, relatively low concentrations of preservatives include concentrations of about 1 μM or less, or about 1% of the pharmaceutical composition by weight or less or about 1 μg per dosage unit of pharmaceutical composition or less.
In other embodiments, relatively low concentrations of preservatives include concentrations of about 100 nM or less, about 10 nM or less, about 1 nM or less, about 100 pM or less, about 10 pM or less or about 1 pM or less; or about 0.1% or less, or about 0.01% or less, or about 0.001% or less or about 0.0001% or less, each of the pharmaceutical composition by weight.
In other embodiments, relatively low amounts of preservatives in pharmaceutical compositions include pharmaceutical compositions wherein preservatives are provided at about 100 ng or less, about 10 ng or less, about 1 ng or less, about 100 pg or less, about 10 pg or less or about 1 pg or less, each per dosage unit of pharmaceutical composition.
The term “anti-oxidant” for the purposes of the present invention refers to a chemical substance that is added to a pharmaceutical composition to prevent or inhibits the oxidation of molecules that are present in the active component of the composition, such as epinephrine. It is explicitly understood that for the purposes of the present application, anti-oxidants are not considered preservatives. Accordingly, compositions that optionally comprise anti-oxidants as described below are considered preservative-free if they include no other preservative(s).
The term “sulfite” refers to compounds that comprise the sulfite ion SO3 2- such as normal salts of sulfurous acid H2SO3. For the purposes of the present application, the term “sulfite” is also inclusive of bisulfites, i.e., compounds that comprise the bisulfate ion HSO3 − such as acid salts of sulfurous acid.
Accordingly “sulfite-free” means a pharmaceutical composition that does not include a sulfite or includes a relatively low concentration or amount of a sulfite. Thus, the pharmaceutical composition can be substantially free of sulfite or have not more than a trace amount of sulfite. It is explicitly understood that for the purposes of the present application, metal chelators such as EDTA defined below are not considered sulfites. Accordingly, compositions that comprise metal chelators such as EDTA are considered sulfite-free if they include no other sulfite(s).
Trace amounts of sulfites can include relatively low concentrations or amounts of sulfites in a pharmaceutical composition. Relatively low concentrations of sulfites include concentrations include concentrations of about 1 μM or less, or about 1% of the pharmaceutical composition by weight or less or about 1 μg per dosage unit of pharmaceutical composition or less.
In other embodiments, relatively low concentrations of sulfites include concentrations of about 100 nM or less, about 10 nM or less, about 1 nM or less, about 100 pM or less, about 10 pM or less or about 1 pM or less; or about 0.1% or less, or about 0.01% or less, or about 0.001% or less or about 0.0001% or less, each of the pharmaceutical composition by weight.
In other embodiments, relatively low amounts of sulfites in pharmaceutical compositions include pharmaceutical compositions wherein preservatives are provided at about 100 ng or less, about 10 ng or less, about 1 ng or less, about 100 pg or less, about 10 pg or less or about 1 pg or less, each per dosage unit of pharmaceutical composition.
The terms “lyophilize” and “lyophilized” refer to the process of freeze-drying (a dehydration process that includes freezing the material and then reducing the pressure to allow the frozen water in the material to sublimate) and to the products of this process.
The term “partially lyophilized” refers to compositions that comprise both a lyophilized portion of a product and a non-lyophilized portion of the same.
The term “epinephrine” which is synonymous with “adrenaline” (the two terms may be used interchangeably) refers to any stereoisomer of 4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol, a chemical compound having the following chemical structure (the R-stereoisomer is shown):
Figure US11045432-20210629-C00001
The term “phenylephrine” refers to any stereoisomer of 3-[1-hydroxy-(methylamino)ethyl]phenol, a chemical compound having the following chemical structure (also the R-stereoisomer is shown):
Figure US11045432-20210629-C00002
The term “EPI-Shugarcaine” refers to a composition consisting of about 25% (vol.) of 1:1,000 bisulfite-free aqueous solution of epinephrine, about 19% (vol.) of preservative-free lidocaine and the balance, BSS Plus® (balanced salt solution available from Alcon Laboratories of Fort Worth, Tex.).
The term “anesthetic” refers to a substance that that causes loss of sensation and therefore induces insensitivity or low sensitivity to pain.
The term “lidocaine” refers to 2-diethylamino-N-(2,6-dimethylphenyl)acetamide, a chemical compound having the following chemical structure:
Figure US11045432-20210629-C00003
The abbreviation “EDTA” is 2-({2[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino) acetic acid (a chemical compound that is also known under several other names such as edetic acid or ethylenediaminetetraacetic), and its various protonated forms, EDTA having the following chemical structure:
Figure US11045432-20210629-C00004
The terms “chelating agent” or “metal chelator” refer to a chemical compound that coordinates with a metal to form a chelate, which is a compound containing an organic ligand bonded to a central metal atom at two or more points.
The terms “non-steroid anti-inflammatory drugs” or “NSAID” refer to a class of compounds that are free of any steroid moieties yet are capable of providing analgesic, antipyretic and/or anti-inflammatory effects.
The term “ketorolac” refers to a chemical composition comprising, in the 1:1 mass ratio, 2-amino-2-(hydroxymethyl)-1,3-propanediol, a chemical compound having the chemical structure NH2—C—(CH2OH)3 and 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, a chemical compound having the following chemical structure:
Figure US11045432-20210629-C00005
The term “salt” refers to an ionic compound which is a product of the neutralization reaction of an acid and a base.
The term “phacoemulsification” refers to an ophthalmological surgical procedure in which the eye's internal lens is ultrasonically emulsified and aspirated from the eye.
The term “carrier” refers to a substance that serves as a vehicle for improving the efficiency of delivery and the effectiveness of a pharmaceutical composition. One non-limiting example of a carrier for the purposes of the instant application is water such as de-ionized sterile water.
The term “therapeutically effective amount” is defined as the amount of the compound or pharmaceutical composition that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, medical doctor or other clinician.
The term “pharmaceutically acceptable” is defined as a carrier, whether diluent or excipient, that is compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The terms “administration of a composition” or “administering a composition” is defined to include an act of providing a compound or pharmaceutical composition of the application to the subject in need of treatment.
B. Embodiments
Intracameral epinephrine is commonly used off-label to dilate and stabilize the pupil intraoperatively by preventing intraoperative floppy iris syndrome. However, as mentioned above, commonly available epinephrine is frequently quite toxic. Those having ordinary skill in the art believe that the toxicity is caused by the high buffer capacity of the bisulfate that is present in the epinephrine solution rather than by the epinephrine itself. It is, therefore, desirable to only use for direct intracameral injection preservative-free preparations of epinephrine that are also bisulfite-free. Another potential problem with undiluted epinephrine taken directly from the vial is that it has a low pH of approximately 3.0, which is well outside the 6.0 to 8.0 pH range thought by those having ordinary skill in the art to be safe for the corneal endothelium.
In view of the foregoing, embodiments described in the present application are directed to pharmaceutical compositions for intraocular injections that are free of the above-mentioned problems, drawbacks and defects. The compositions are preservative-free and sulfite-free and include an active component comprising, consisting essentially of, or consisting of a therapeutically effective quantity of epinephrine or adrenaline or pharmaceutically acceptable salts thereof (e.g., a hydrochloride) and a pharmaceutically acceptable carrier therefor. Bisulfite-free epinephrine is available from American Regent Laboratories of Shirley, N.Y.
In addition to epinephrine, the active component may optionally include other compounds, non-limiting examples of which include phenylephrine, EPI-Shugarcaine and/or tropicamide. Some anti-oxidants may be also optionally used, if desired, as a part of the active component, i.e., in combination with epinephrine, to provide some additional stability to epinephrine. Non-limiting examples of acceptable anti-oxidants that may be so used include ascorbic acid, vitamin E, glutathione and acetylcysteine. It has to be kept in mind that these additional anti-oxidants typically provide only limited stability to epinephrine, usually up to 60 days, when the composition is kept refrigerated.
In some further embodiments, the active component may optionally include still other compounds, such as one or several anesthetics (e.g., lidocaine) and/or one or several non-steroid anti-inflammatory drug(s). Non-limiting examples of alternative acceptable anesthetics that may be used in any combination with, or instead of, lidocaine, include proparacaine, procaine, tetracaine and combinations thereof. Non-limiting examples of acceptable NSAID's that can be so utilized include ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.
In sum, embodiments of the invention envision preservative-free and sulfite-free compositions having an active component, which includes any combination of epinephrine, and/or phenylephrine and/or EPI-Shugarcaine, and in addition, optionally, any combination of anesthetic(s) and/or non-steroid anti-inflammatory drug(s). In other words, at least one of epinephrine, phenylephrine EPI-Shugarcaine and tropicamide is to be present in the active component, while the presence of any other additional components mentioned above is optional.
The contents of the active component in the pharmaceutical compositions of the present application may be between about 0.001 and about 0.5 mass %, such as between about 0.01 and about 0.3 mass %, for example, between about 0.03 and about 0.1 mass %. The compositions described in the present application further include certain additives, but, as indicated above, are free of preservatives and are free of sulfites. If NSAID(s) are to be used, one having ordinary skill in the art may select a proper ratio between epinephrine, and/or phenylephrine and/or EPI-Shugarcaine and NSAID(s). In exemplary, non-limiting embodiments, the mass ratio between phenylephrine and ketorolac may be between about 10:1 and about 3:1, such as about 4:1.
According to embodiments of the present invention, a pharmaceutical composition for intraocular injection further comprises a quantity of least one chelating agent such as a metal chelator. One non-limiting example of an acceptable chelating agent that may be used in combination with epinephrine is ethylenediaminetetraacetic acid (EDTA) or pharmaceutically acceptable salts thereof, which is both a chelator and a stabilizer. One salt of EDTA that can provide stabilization of epinephrine is EDTA disodium. Other salts of EDTA, non-limiting examples of which include EDTA calcium disodium and EDTA magnesium disodium, may be also used instead of, or in combination with, EDTA disodium.
The contents of the chelating agent in the pharmaceutical compositions of the present application may be (expressed as the chelating agent to epinephrine mass ratio) between about 4:1 and 1:4, for example, about 1:2 (i.e., about 0.5 mg of EDTA per 1 mg of epinephrine). Those having ordinary skill in the art may select a specific chelating agent based on the needs of a particular patient or on the desired properties of the final composition and may also adjust the concentration of the active component and/or of the chelating agent in the composition, if desired.
In addition to the active component(s), chelating agent(s), anesthetic(s) and/or non-steroid anti-inflammatory drug(s), the composition may optionally include other components such as additives, adjuvants, diluents, modifiers, excipients, etc., so long as the composition remains both preservative-free and sulfite-free within the meaning of “preservative” defined above. Some non-limiting examples of such optionally useful suitable additives, diluents, adjuvants, modifiers, or excipients include acetylcysteine (acetylcysteine which is capable of eliminating, or at least reducing the quantity of, free radicals, and of providing nourishment to the eye), glutathione, ascorbic acid, vitamin E and balanced salts solution.
A variety of suitable methods are envisioned that one having ordinary skill in the art may employ to prepare preservative-free and sulfite-free epinephrine-based pharmaceutical compositions for intraocular injection according to embodiments described in the instant application. According to one non-limiting embodiment, composition I can be prepared first. To prepare composition I, a quantity of an active ingredient such as epinephrine, a quantity of a metal chelator such as EDTA, optionally, a quantity of at least one anesthetic, optionally, a quantity of at least one non-steroid anti-inflammatory drug and, optionally, a quantity of an non-preservative additive such as sodium chloride NaCl (e.g., if isotonicity has to be adjusted), may be combined in a depyrogenated glass container. The mixture may be then dissolved in sterile de-ionized water to form a clear aqueous solution.
Each of the ingredients used to make composition I is to be used in pre-determined quantity so that the final pharmaceutical composition have a desired ratio between the ingredients and a desired concentration of each of them. Those having ordinary skill in the art can determine the desired ratios and concentrations. The pH of the solution may be adjusted to a pH level ranging from slightly acidic, e.g., about 6.0, to slightly basic, e.g., about 8.0. The process of lyophilization of composition I may then be conducted to obtain the lyophilized product, composition II.
To conduct the process of lyophilization, the solution may be optionally de-gassed followed by freezing at low temperatures (e.g., −70° C. or lower) for a period of time (e.g., at least 24 hours) to allow the solution to completely solidify and to form proper ice crystals. Then, the frozen composition is subjected to a vacuum of at least 30 mm Hg for a period of time (e.g., at least 24 hours). As a result of exposure to the vacuum, the water sublimates from the frozen solution (i.e., transitions from the solid to the gas phase bypassing the liquid phase) to form a completely dry, powder-like substance which is the lyophilized composition II. Accordingly, composition II is a completely lyophilized preservative-free and sulfite-free pharmaceutical composition containing the active ingredient (e.g., epinephrine), the metal chelator (e.g., EDTA) and, optionally, other ingredients discussed above, if such optional ingredients are used in preparing composition I. Not more than trace quantity of residual water would be typically contained in composition II after the process of lyophilization is complete.
Composition II, i.e., the lyophilized dry epinephrine-based composition that is preservative-free and sulfite-free prepared according to methods described herein has remained stable for several months and is expected to continue being stable for as long as two years. Stability can be evaluated by those having ordinary skill in the art according to one or more of various methods, e.g., by the retention of potency after storage for a period of time, by showing that no loss (or not more than negligible loss) of concentration of epinephrine has occurred during the period of storage, or by visual observations such as no change in color.
Next, the dry composition II is to be reconstituted immediately prior to its use, for example, 1 hr or less before the surgery, or 30 minutes or less. To reconstitute the composition, a quantity of sterile de-ionized water for injection is to be added to the dry composition and a clear solution can thus obtained. The concentration of the active component such as epinephrine that is desirable to have for the injection determines the quantity of water to be added to the dry composition, to be chosen by one having ordinary skill in the art. In one exemplary non-limiting embodiment, the final product to be injected contains about 1 mg/mL of epinephrine, i.e., is a 1:1,000 solution.
As is clear from the discussion above, the use of lyophilized and then reconstituted composition II is then typically envisioned according to embodiments of the instant application. However, in other embodiments that can be also practiced, composition I described above may be optionally used for re-constitution, with or without pure sterile de-ionized water for injection being added also. Thus, in such optional embodiments, the pharmaceutical composition comprises a fully lyophilized portion (i.e., composition II), a non-lyophilized portion (i.e., composition I) and, optionally, an extra quantity of pure sterile de-ionized water. Those having ordinary skill in the art can determine the quantities of the fully lyophilized and non-lyophilized portions and of water so as to achieve the desired ratios of the ingredients and their concentrations.
A variety of apparatuses can be used for reconstituting the composition. For example, water can be added to the dry composition in a single container such as a vial. Once a clear solution has been formed, it can be collected by a syringe and injected or it can be picked up by an eye dropper or a pipette and administered as drops, if desired. Those skilled in the art will use an appropriate apparatus if the composition is to be administered as a spray. Alternatively, the dry composition can be mixed with sterile water or with a balanced salt solution in an infusion bottle, to be delivered in the phacoemulsification procedure if desired.
In yet another alternative embodiment, a bicameral container can be used. Those having ordinary skill in the art can devise such a bicameral container. For instance, in a typical bicameral container, there may be two sections separated by a partition or a seal. One section will contain the dry composition described above and the second section will contain sterilized water. The partition (or the seal) will prevent the contents of the two sections from combining. When needed, the partition (or the seal) can be eliminated or pierced thus allowing the contents of both sections to mix to form a clear solution to be administered to the patient.
In one particular embodiment a bicameral container 100 illustrated schematically by FIG. 1 may be used. In this embodiment, the bicameral container 100 having essentially a cylindrical shape comprises first section 1 into which a quantity of lyophilized composition 2 is placed. Container 100 further comprises second section 3 into which a quantity of a carrier (i.e., in this embodiment sterilized water) 4 is placed. The two sections are separated by partition 5 which prevents lyophilized composition 2 from uncontrollably mixing with water 4. To insure that lyophilized composition 2 and water 4 are kept separate, in some embodiments, partition 5 may include a one-way valve (not shown). Any typical standard one-way valve known to those having ordinary skill in the art may be utilized for this purpose.
It is further provided that in some embodiments (not shown) the lyophilized composition 2 and water 4 may change places, i.e., the lyophilized composition 2 may be placed into the second section 3 and water 4 into the first section 1. Other features described above remain the same, i.e., the container 100 still includes partition 5.
To operate the device 100, in order to reconstitute lyophilized composition 2, a pressure may be applied to carrier 4 using moveable plunger 6. Under pressure, the valve opens thus eliminating the partition between sections 1 and 3 and allowing carrier 4 to flow from section 3 into section 1 to mix with the lyophilized composition 2. As a result a reconstituted pharmaceutical composition is obtained, to be administered to a patient.
Those having ordinary skill in the art may employ another method of breaking partition 5 if desired. Designing such alternative method of removing the partition is well within the scope of knowledge of those having ordinary skill in the art. For example, the plunger 6 can comprise a protrusion or puncture component on the partition facing surface of the plunger 6 which when directional force is applied to the plunger the protrusion or puncture component pierces the partition 5 and allows the carrier 4 to flow from the second section 3 into the first section 1. After the pharmaceutical composition has been reconstituted in a liquid form as described above, a needle or a cannula (not shown) may be attached to device 100 at point 7, and the composition may be then injected by using the device 100 (with the needle attached to it) as a syringe.
In one further embodiment, the process of lyophilization described above may be carried out directly in the device 100. To wit, a liquid composition 6 may be placed into section 1 of the device 100 prior to being lyophilized, followed by lyophilization by vacuum freeze-drying as discussed above, i.e, thereby producing lyophilized composition 2. When the process of lyophilization is thus completed, section 1 of the device 100 will have lyophilized composition 2 contained within section 1 followed by the process of reconstituting lyophilized composition 2 as described above.
The reconstituted composition can then be used for surgically treating an ophthalmological disease, condition, disorder, syndrome or pathology in a mammalian subject such a human when it is necessary to administer an active component described in the application, e.g., epinephrine, as a part of surgical treatment. In addition to humans, the reconstituted composition can be also used for treating of variety of animals, such as cats, dogs and farm animals if necessary.
Non-limiting examples of the ophthalmological disease, condition, disorder, syndrome or pathology to be treated include cataract surgery, glaucoma surgery, surgery to treat diseases of retina and prevention of floppy iris syndrome that may otherwise occur during other kinds of eye surgery. While it is envisioned that the above described compositions are primarily to be delivered to an eye of the patient by an intraocular injection, some alternative methods of delivery may be also acceptable if desired. Examples of such alternative methods include delivery via eye drops or via a spray as mentioned above. Those skilled in the art will formulate most appropriate eye drop and/or spray formulation(s) using lyophilized compositions described above, according to the best pharmaceutical practices.
It will be understood by those having ordinary skill in the art that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, gender, diet, and the severity of the particular ophthalmological condition being treated.
In additional embodiments, pharmaceutical kits are provided. The kit includes a sealed container approved for the storage of pharmaceutical compositions, the container containing one of the above-described pharmaceutical compositions. An instruction for the use of the composition and the information about the composition are to be included in the kit.
The following examples are provided to further elucidate the advantages and features of the present application, but are not intended to limit the scope of the application. The examples are for the illustrative purposes only. USP pharmaceutical grade products were used in preparing the formulations described below.
Example 1 Preparing a Pharmaceutical Composition
A pharmaceutical composition was prepared as described below. The following products were used in the amounts and concentrations specified, sufficient to prepare 100 vials of 1:1,000 lyophilized injections (1 mg/mL): 1.2 mg per vial.
(1) about 0.120 g of DL-epinephrine HCl hydrochloride;
(2) about 0.80 g of sodium chloride;
(3) about 0.01 g of edetate disodium;
(4) about 0.01 g of acetylcysteine;
(5) hydrochloric acid/sodium hydroxide, for pH adjustment; and
(6) about 100 ml of sterile water for injection, quantum sufficiat.
Components shown above were protected from light and air to minimize oxidation and degradation. Half the volume of sterile water for injection was added to a depyrogenated glass vessel followed by components (1)-(4) in the quantities shown above. Sufficient quantity of sterile water for injection was then added to obtain a required volume. So combined products were then mixed until completely dissolved and a clear solution was obtained. pH of the solution was adjusted to about 6.0 with hydrochloric acid and/or sodium hydroxide. Further processing described below was completed in a clean room.
The solution obtained as described above was filtered through 0.22 micron Supor filters into depyrogenated, sterilized (by autoclaving) vials, partially capped with three prong lyophilization stoppers and immediately frozen at about −71° C. for about 24 hours to allow complete freezing and proper ice crystal formation. Degassing of solution prior to freeze-drying is optional but not necessary in this method.
Frozen vials were then placed into vacuum chamber, vacuum drawn and freeze drying process commenced. Two stage drying process (primary and secondary drying) over the next 24 hours took place during this time. When completed, vials were fully stoppered and sealed. Powder cake present inside vial was completely dry, stable and both sulfite free and preservative free.
The final product was tested chromatographically (HPLC) for potency and stability after being stored for some time. After about 5 weeks and again after about 4 months it remained stable and has retained its potency. No visually perceptible change of color has been observed.
Example 2 Re-Constituting a Lyophilized Pharmaceutical Composition
The composition prepared as described in Example 1 was then re-constituted about 30 minutes prior to being administered to a patient. A quantity of sterile water for injection was added to the dry composition prepared as described in Example 1 in a vial and a clear solution was obtained. The final product ready for injection contained about 1 mg/mL of epinephrine, i.e., was a 1:1,000 aqueous solution.
Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

Claims (7)

What is claimed is:
1. A method for preparing an aqueous ophthalmic pharmaceutical composition, the method consisting of combining:
(1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;
(2) at least one metal chelator, wherein the metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof;
(3) optionally, at least one anesthetic;
(4) optionally, at least one tonicity adjusting agent comprising sodium chloride;
(5) optionally, hydrochloric acid and/or sodium hydroxide;
(6) optionally, at least one non-steroid anti-inflammatory drug; and
(7) a quantity of sterile water,
wherein the composition is free of sulfites, is free of preservatives and has a pH above 6.0 and below 8.0;
thereby preparing the aqueous ophthalmic pharmaceutical composition.
2. The method of claim 1, wherein epinephrine is in the form of epinephrine hydrochloride.
3. The method of claim 1, wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.
4. The method of claim 1, wherein the at least one anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.
5. The method of claim 1, wherein the at least one non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.
6. The method of claim 1, wherein the therapeutically effective quantity of at least one compound is selected from the group consisting of epinephrine, EPI-Shugarcaine and tropicamide.
7. The method of claim 1, wherein the aqueous composition consists of tropicamide, phenylephrine HCl, at least one metal chelator wherein the metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, lidocaine HCl, at least one tonicity adjusting agent wherein the tonicity adjusting agent is sodium chloride, hydrochloric acid and/or sodium hydroxide, and sodium diclofenac in sterile water.
US15/247,524 2013-10-03 2016-08-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof Active US11045432B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/247,524 US11045432B2 (en) 2013-10-03 2016-08-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US17/330,023 US20210275471A1 (en) 2013-10-03 2021-05-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US17/384,373 US20210346318A1 (en) 2013-10-03 2021-07-23 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361886269P 2013-10-03 2013-10-03
US201361892872P 2013-10-18 2013-10-18
US201461947778P 2014-03-04 2014-03-04
US14/506,120 US10993921B2 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US15/247,524 US11045432B2 (en) 2013-10-03 2016-08-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/506,120 Continuation-In-Part US10993921B2 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/330,023 Continuation US20210275471A1 (en) 2013-10-03 2021-05-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Publications (2)

Publication Number Publication Date
US20170049721A1 US20170049721A1 (en) 2017-02-23
US11045432B2 true US11045432B2 (en) 2021-06-29

Family

ID=52779188

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/506,120 Active US10993921B2 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US15/241,958 Abandoned US20160354308A1 (en) 2013-10-03 2016-08-19 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US15/247,524 Active US11045432B2 (en) 2013-10-03 2016-08-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US17/330,023 Abandoned US20210275471A1 (en) 2013-10-03 2021-05-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US14/506,120 Active US10993921B2 (en) 2013-10-03 2014-10-03 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US15/241,958 Abandoned US20160354308A1 (en) 2013-10-03 2016-08-19 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/330,023 Abandoned US20210275471A1 (en) 2013-10-03 2021-05-25 Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Country Status (10)

Country Link
US (4) US10993921B2 (en)
EP (1) EP3052095A4 (en)
JP (2) JP2016532723A (en)
KR (1) KR20160070077A (en)
AU (2) AU2014329412B2 (en)
BR (1) BR112016007328A2 (en)
CA (1) CA2925008A1 (en)
IL (1) IL244687A0 (en)
MX (1) MX2016004257A (en)
WO (1) WO2015051264A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016532723A (en) 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Epinephrine-based eye drop composition for intraocular administration and method for its manufacture
TWI809304B (en) * 2014-12-01 2023-07-21 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
US20190350881A1 (en) * 2016-06-17 2019-11-21 Ys Pharmtech Stabilization of epinephrine formulations
JP2019524896A (en) * 2016-08-25 2019-09-05 ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． Epinephrine-based ophthalmic composition for intraocular administration and method for producing the same
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
US11925608B2 (en) * 2017-09-26 2024-03-12 Ys Pharmtech Stabilization of epinephrine formulations
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
WO2019183416A1 (en) * 2018-03-23 2019-09-26 Nevakar Inc. Epinephrine compositions and containers
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
US4590210A (en) 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
CA2002643A1 (en) 1988-11-09 1990-05-09 Maryjane Helenek Antioxidant-free epinephrine solution for ophthalmic use
WO1994008602A1 (en) 1992-10-21 1994-04-28 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5709852A (en) 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
WO1998003641A1 (en) 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
FR2779061A1 (en) 1998-04-14 1999-12-03 Pharmatop Stabilized solution for injection of pharmaceutically active phenolic compounds
WO2002026223A2 (en) 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20020146375A1 (en) 1998-12-22 2002-10-10 Jorg Schreiber Cosmetic or pharmaceutical lecithin-containing gels or low viscosity lecithin-containing O/W microemulsions
US6562002B1 (en) 1999-02-16 2003-05-13 Prismedical Corporation Single dose delivery device
WO2004010894A2 (en) 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
US20040076588A1 (en) 2002-06-28 2004-04-22 Batycky Richard P. Inhalable epinephrine
US20050074414A1 (en) 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050118231A1 (en) * 2001-12-18 2005-06-02 Said El Meski Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
US20050176823A1 (en) 2004-02-10 2005-08-11 Diaz Robert L. Intra-operative procedure for post-operative pain control
US20070060877A1 (en) * 2005-08-13 2007-03-15 Stefan Bassarab Dual chamber container for lyophilization, process for the filling up and use thereof
US20070196324A1 (en) 2006-02-01 2007-08-23 Keefe Candace R Cellulite skin treatment methods and compositions
WO2007122580A2 (en) * 2006-04-21 2007-11-01 The Procter & Gamble Company Compositions of phenylephrine useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
WO2009111083A2 (en) 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes
WO2010057007A1 (en) 2008-11-14 2010-05-20 Archer Daniels Midland Company Organogel compositions and processes for producing
EP2246045A1 (en) * 2007-08-13 2010-11-03 McNeil-PPC, Inc. Method for stabilizing phenylephrine
US20120129944A1 (en) 2009-06-04 2012-05-24 Alk Ag Stabilized composition comprising at least one adrenergic compound
US20120220637A1 (en) * 2005-03-09 2012-08-30 Walild Khatib Ophthalmologic Compositions And Use Mode Thereof
US20130210840A1 (en) 2010-06-11 2013-08-15 Imprimis Pharmaceuticals, Inc. Anti-Cellulite Composition and Method of Treating Cellulite
US20140235691A1 (en) * 2012-10-24 2014-08-21 Omeros Corporation Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection
US20150017151A1 (en) 2013-06-18 2015-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US20150119440A1 (en) 2013-10-03 2015-04-30 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US9301936B2 (en) 2013-07-08 2016-04-05 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
US10285957B2 (en) * 2016-08-25 2019-05-14 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9102148A (en) * 1991-12-20 1993-07-16 Dsm Nv COPOLYMER OF LACTON AND CARBONATE AND METHOD FOR OBTAINING IT.
CN101444481A (en) 2009-01-06 2009-06-03 河北科技大学 Tropicamide eye drops without bacteria inhibitor and the preparation method thereof
KR20140112825A (en) 2013-03-14 2014-09-24 삼성전자주식회사 Method and apparatus for electronic settlement in a electronic device

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3808317A (en) 1969-10-29 1974-04-30 Alcon Labor Inc Stabilized aqueous borate complexes of biologically active catechol amines
US4590210A (en) 1979-03-09 1986-05-20 Langham Maurice E Compositions for treatment of ocular hypertension
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4550022A (en) 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
CA2002643A1 (en) 1988-11-09 1990-05-09 Maryjane Helenek Antioxidant-free epinephrine solution for ophthalmic use
WO1994008602A1 (en) 1992-10-21 1994-04-28 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
JPH07502544A (en) 1992-10-21 1995-03-16 アルコン　ラボラトリーズ，インコーポレイテッド Composition for intraocular tissue irrigation and for maintaining pupil dilation during intraocular surgical procedures
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
US5709852A (en) 1995-12-05 1998-01-20 Basf Corporation Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends
WO1998003641A1 (en) 1996-07-23 1998-01-29 Crandall Wilson T Transdermal transport of molecules
FR2779061A1 (en) 1998-04-14 1999-12-03 Pharmatop Stabilized solution for injection of pharmaceutically active phenolic compounds
US20020146375A1 (en) 1998-12-22 2002-10-10 Jorg Schreiber Cosmetic or pharmaceutical lecithin-containing gels or low viscosity lecithin-containing O/W microemulsions
US6562002B1 (en) 1999-02-16 2003-05-13 Prismedical Corporation Single dose delivery device
WO2002026223A2 (en) 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine pharmaceutical compositions and methods
US20030216413A1 (en) 2000-09-29 2003-11-20 Root-Bernstein Robert S. Catecholamine pharmaceutical compositions and methods
JP2004509920A (en) 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ Catecholamine pharmaceutical compositions and methods
US20050118231A1 (en) * 2001-12-18 2005-06-02 Said El Meski Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
US20040076588A1 (en) 2002-06-28 2004-04-22 Batycky Richard P. Inhalable epinephrine
US20110237681A1 (en) 2002-06-28 2011-09-29 Civitas Therapeutics, Inc. Inhalable epinephrine
US20040072809A1 (en) 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
WO2004010894A2 (en) 2002-07-30 2004-02-05 Omeros Corporation Ophthalmologic irrigation solutions and method
JP2006504661A (en) 2002-07-30 2006-02-09 オメロス コーポレイション Ophthalmological cleaning solution and ophthalmological cleaning method
US20100311705A1 (en) * 2002-07-30 2010-12-09 Omeros Corporation Ophthalmologic irrigation solutions and method
US20050074414A1 (en) 2002-10-25 2005-04-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050176823A1 (en) 2004-02-10 2005-08-11 Diaz Robert L. Intra-operative procedure for post-operative pain control
US20120220637A1 (en) * 2005-03-09 2012-08-30 Walild Khatib Ophthalmologic Compositions And Use Mode Thereof
US20070060877A1 (en) * 2005-08-13 2007-03-15 Stefan Bassarab Dual chamber container for lyophilization, process for the filling up and use thereof
US20070196324A1 (en) 2006-02-01 2007-08-23 Keefe Candace R Cellulite skin treatment methods and compositions
WO2007122580A2 (en) * 2006-04-21 2007-11-01 The Procter & Gamble Company Compositions of phenylephrine useful for treatment of respiratory illness
US20080269347A1 (en) * 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
US20090017120A1 (en) 2007-03-23 2009-01-15 Humco Holding Group, Inc. Phase stable lecithin organogel composition
EP2246045A1 (en) * 2007-08-13 2010-11-03 McNeil-PPC, Inc. Method for stabilizing phenylephrine
WO2009111083A2 (en) 2008-03-06 2009-09-11 Halozyme, Inc. In vivo temporal control of activ at able matrix- degrading enzymes
WO2010057007A1 (en) 2008-11-14 2010-05-20 Archer Daniels Midland Company Organogel compositions and processes for producing
US20120129944A1 (en) 2009-06-04 2012-05-24 Alk Ag Stabilized composition comprising at least one adrenergic compound
US20130210840A1 (en) 2010-06-11 2013-08-15 Imprimis Pharmaceuticals, Inc. Anti-Cellulite Composition and Method of Treating Cellulite
US20140235691A1 (en) * 2012-10-24 2014-08-21 Omeros Corporation Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection
US20150017151A1 (en) 2013-06-18 2015-01-15 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US9301936B2 (en) 2013-07-08 2016-04-05 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
US20150119440A1 (en) 2013-10-03 2015-04-30 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JP2016532723A (en) 2013-10-03 2016-10-20 インプリミス・ファーマシューティカルズ・インコーポレイテッドＩｍｐｒｉｍｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Epinephrine-based eye drop composition for intraocular administration and method for its manufacture
US20160354308A1 (en) 2013-10-03 2016-12-08 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US10285957B2 (en) * 2016-08-25 2019-05-14 Imprimis Pharmaceuticals, Inc. Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Non-Patent Citations (27)

* Cited by examiner, † Cited by third party
Title
American Reagent Laboratories, Inc., MSDS of Epinephrine Injection from Lutipold Pharmaceuticals, 1998, 4 pages.
BSS Product Page. Alcon Laboratories, Inc. (2012).
Das Gupta etal (J. Clin. Hosp Pharm vol. 11 pp. 449-452. Published 1986). (Year: 1986). *
Das Gupta, V., J. Clin. Hosp Pharm vol. 11 pp. 449-452. Published 1986. (Year: 1986). *
Grubstein, B. et al., Stabilization of Epinephrin in a local anesthetic injectable solution using reduced levels of Sodium Metabisulfite and EDTA. Drug Development and Industrial Pharmacy. vol. 18, pp. 1549-1566 (1992).
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/059077, dated Jan. 26, 2015.
Lorenzetti, "Dose-dependent Influence of Topically Instilled Adrenergic Agents on Intraocular Pressure and Outflow Facility in the Rabbit", Exp Eye Res, 1971, vol. 12, pp. 80-87.
Non-Final Rejection corresponding to U.S. Appl. No. 14/506,120, dated Oct. 5, 2017, 28 pages.
Overgaard (2006) "How to Make Sterile Water and Sterile Saline," Phoenix Children's Hospital.
PCT/US2014/059077, filed Oct. 3, 2014, John Scott Karolchyk.
PH. Encyclopedia Britannica. Published online 1998 (Year: 1998). https://www.britannica.com/science/pH. 10 pages.
Remington, The Science and Practice of Pharmacy, 21st Edition, 2005, pp. 828-829.
Roscoe et al., "Chelating Agents as Color Stabilizers for Epinephrine Hydrochloride Solutions", Journal of the American Pharmaceutical Association, 1956, vol. 45, No. 7, pp. 464-470.
Schulze Jr., R, (2010) "Epi-Shugarcane with plain balanced salt solution for prophylaxis of intraoperative floppy-iris syndrome," Journal of Cataract and Refractive Surgery. 36:523.
Schulze Jr., Richard (Mar. 2010) "EPI-Shugarcaine With Plain Balanced Salt Solution for Prophylaxis of Intraoperative Floppy-Iris Syndrome," J Cataract Surg vol. 35, pp. 523.
Shugar et al. (2006) "Use of epinephrine for IFIS prophylaxis," Journal of Cataract & Refractive Surgery. 32 (7):1074-1075.
Shugar, J. K. (Sep. 2006) "Intracameral Epinephrine for IFIS Prophylaxis," Cataract & Refractive Surgery Today. pp. 1-13.
Sinnott et al. (2003) "On the mechanism by which epinephrine potentiates lidocaine's peripheral nerve block," The Journal of the American Society of Anesthesiologists. 98(1):181-188.
Slack (American Journal of Ophthalmology vol. 110 p. 77-82 published 1990). (Year: 1990). *
Stewart, R. et al, (1999) "Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery," Clinical Therapeutics. 21:723-732.
U.S. Appl. No. 14/506,120, filed Oct. 3, 2014, John Scott Karolchyk.
U.S. Appl. No. 15/241,958, filed Aug. 19, 2016, John Scott Karolchyk.
United States Pharmacopoeia 21st Review, National Formulary 16th Review, 1985, pp. 1651, 592-596, 1662, 571-572, 827-830, 883-884.
Verhoff, F. et al. Ulmann's Encyclopedia of Industrial Chemistry: Citric Acid. Wiley-VCH GmBH & Co. KGaA, Weinheim. pp. 1-9. (2015).
West et al (Journal of Pharmacy and Pharmacology vol. 12 p. 113T-115T Published 1960). (Year: 1960). *
West, G.B., Journal of Pharmacy and Pharmacology vol. 12 p. 113T-115T Published 1960. (Year: 1960). *
Zhang et al. (2006) "Study of mixed micelles and interaction parameters for polymeric nonionic and normal sufactants," Journal of Nanoscience and Nanotechnology.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230277694A1 (en) * 2022-03-04 2023-09-07 Harrow Ip, Llc Ophthalmic dye composition and method for administering same

Also Published As

Publication number Publication date
AU2014329412B2 (en) 2020-02-27
US10993921B2 (en) 2021-05-04
CA2925008A1 (en) 2015-04-09
US20160354308A1 (en) 2016-12-08
EP3052095A4 (en) 2017-07-05
KR20160070077A (en) 2016-06-17
US20150119440A1 (en) 2015-04-30
JP2016532723A (en) 2016-10-20
AU2014329412A1 (en) 2016-05-05
MX2016004257A (en) 2016-08-17
WO2015051264A1 (en) 2015-04-09
AU2020203044A1 (en) 2020-05-28
US20170049721A1 (en) 2017-02-23
EP3052095A1 (en) 2016-08-10
BR112016007328A2 (en) 2017-08-01
IL244687A0 (en) 2016-04-21
WO2015051264A8 (en) 2016-04-07
US20210275471A1 (en) 2021-09-09
JP2019142964A (en) 2019-08-29

Similar Documents

Publication Publication Date Title
US20210275471A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US10285957B2 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US11179404B2 (en) Formulations of deoxycholic acid and salts thereof
ES2875432T3 (en) Stable, preservative-free anti-inflammatory and mydriatic solutions for injection
AU2011281035B2 (en) Acetycysteine compositions and methods of use thereof
RU2392925C2 (en) New ophthalmic compositions and methods of application thereof
US20210346318A1 (en) Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20240058320A1 (en) Mydriatic compositions and methods for fabricating thereof
JPH09506620A (en) Improved intraocular irrigation solution containing non-steroidal anti-inflammatory agents
US7169812B2 (en) Process for producing injectable gabapentin compositions
MXPA94003569A (en) Stable quinolone and naphthyridine premix formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMPRIMIS PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAROLCHYK, JOHN SCOTT;BAUM, MARK L.;SIGNING DATES FROM 20161006 TO 20161007;REEL/FRAME:039995/0588

AS Assignment

Owner name: SWK FUNDING LLC, AS COLLATERAL AGENT, TEXAS

Free format text: INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:IMPRIMIS PHARMACEUTICALS, INC.;REEL/FRAME:043258/0581

Effective date: 20170719

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

AS Assignment

Owner name: HARROW IP, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IMPRIMIS PHARMACEUTICALS, INC.;REEL/FRAME:050985/0969

Effective date: 20191112

AS Assignment

Owner name: SWK FUNDING LLC, AS COLLATERAL AGENT, TEXAS

Free format text: AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNOR:HARROW IP, LLC;REEL/FRAME:051079/0453

Effective date: 20191114

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

AS Assignment

Owner name: HARROW IP, LLC, TENNESSEE

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SWK FUNDING LLC;REEL/FRAME:056174/0332

Effective date: 20210430

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT, CALIFORNIA

Free format text: SECURITY INTEREST;ASSIGNORS:HARROW HEALTH, INC.;HARROW EYE, LLC;HARROW IP, LLC;AND OTHERS;REEL/FRAME:062105/0556

Effective date: 20221214

AS Assignment

Owner name: VISIONOLOGY MSO, INC., CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: VISIONOLOGY, INC., CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: VISIONOLOGY EQUITY, LLC, CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: IMPRIMISRX NJ, LLC, NEW JERSEY

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: IMPRIMIS NJOF, LLC, NEW JERSEY

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: IMPRIMISRX, LLC, CALIFORNIA

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: HARROW IP, LLC, TENNESSEE

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: HARROW EYE, LLC, TENNESSEE

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: HARROW HEALTH, INC., TENNESSEE

Free format text: TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556;ASSIGNOR:B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT;REEL/FRAME:063205/0889

Effective date: 20230327

Owner name: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT, CALIFORNIA

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:HARROW IP, LLC;REEL/FRAME:063205/0708

Effective date: 20230327